Search
for

    Sort by

    Community Join

    990-1000 / 1000+ results

      community I hope ET-02 or PP405 will be released in the next 4-5 years

      in Product  15 upvotes 1 year ago
      PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.

      community So... any chinese suppliers for real pyri?

      in Research/Science  6 upvotes 1 year ago
      The conversation discusses sourcing pyrilutamide from China for hair loss treatment, highlighting its potency compared to other AR antagonists like bicalutamide and RU58841. The user expresses interest in trying pyrilutamide despite mixed results in clinical trials.

      community Pp405 - lowkey kinda bad results

      in Treatment  16 upvotes 11 months ago
      PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

      community 13 WEEKS MICRONEEDLING MONOTHERAPY

      in Microneedling  187 upvotes 3 years ago
      A user's experience with microneedling monotherapy and potential treatments such as finasteride, minoxidil, Stemoxydine, rosemary oil, peppermint oil, and RU58841 for reversing hair loss.

      community Microneedling only with rosemary

      in Microneedling 2 years ago
      A user asked if microneedling, massages, and essential oils can prevent further hair loss in the crown area without using drugs. The response indicated that without a 5-alpha-reductase inhibitor, hair loss will likely continue.

      community Research about RU58841 /Why it was stopped

      in Research/Science  29 upvotes 5 years ago
      RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.